Vectus Biosystems Limited (VBS)

Overview

Vectus Biosystems Limited is an innovative medical research and development company based in North Ryde, Australia, founded in 2005. Specializing in the creation of treatments for heart, kidney, liver, and lung diseases, their primary focus is on addressing cardiovascular fibrosis and systolic blood pressure. Through their advanced research efforts, Vectus Biosystems is dedicated to developing solutions aimed at treating the complications of fibrosis and scarring, alongside battling high blood pressure, thereby improving patient outcomes across several critical health areas.

Products and Services

• VB0004: Vectus Biosystems' lead compound, VB0004, is at the forefront of their research and development efforts. It targets the loss of functional tissue due to fibrosis and scarring while also addressing high blood pressure. This compound holds the potential to revolutionize treatment strategies for various diseases by reversing or halting the progression of tissue damage.
• VB4-A32: Specifically designed for the treatment of liver fibrosis, VB4-A32 represents Vectus Biosystems' commitment to combating liver diseases. Liver fibrosis, which can progress to cirrhosis if left untreated, poses a significant health risk. The development of VB4-A32 showcases the company's innovative approach to tackling such severe conditions through targeted therapeutic interventions.
• VB4-A79: Addressing lung fibrosis, VB4-A79 is another key compound in Vectus Biosystems' product pipeline. Lung fibrosis leads to a deteriorating quality of life and can be fatal. By focusing on this area, Vectus demonstrates their dedication to expanding treatment options for patients suffering from debilitating pulmonary conditions.
• Accugen: Beyond disease treatment compounds, Vectus Biosystems offers Accugen – a sophisticated platform that includes AccuCal and RealCount software. This technology enhances the efficiency, speed, and accuracy of measuring DNA and RNA quantities in laboratory samples. Accugen exemplifies Vectus Biosystems' commitment not just to therapeutics but also to advancing research methodologies and laboratory practices.